doi:10.19982/j.issn.1000-6621.20220515

Abstract

CLC Number:

R563

References 19

[1]	Winthrop KL, Marras T, Adjemian J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U. S. managed care health plan, 2008—2015. Ann Am Thorac Soc, 2020, 17(2):178-185. doi:10.1513/AnnalsATS.201804-236OC. doi: 10.1513/AnnalsATS.201804-236OC pmid: 31830805
[2]	Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med, 2010, 182(7): 970-976. doi:10.1164/rccm.201002-0310OC. doi: 10.1164/rccm.201002-0310OC URL
[3]	Lee H, Myung W, Koh WJ, et al. Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007—2016. Emerg Infect Dis, 2019, 25(3):569-572. doi:10.3201/eid2503.181597. doi: 10.3201/eid2503.181597 URL
[4]	Kumar K, Loebinger MR. Nontuberculous mycobacterial pulmonary disease: clinical epidemiologic features, risk Factors, and diagnosis: the nontuberculous mycobacterial series. Chest, 2022, 161(3):637-646. doi:10.1016/j.chest.2021.10.003. doi: 10.1016/j.chest.2021.10.003 URL
[5]	Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis, 1990, 142(4):940-953. doi:10.1164/ajrccm/142.4.940. doi: 10.1164/ajrccm/142.4.940 URL
[6]	Hwang JA, Kim S, Jo KW, et al. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J, 2017, 49(3): 1600537. doi:10.1183/13993003.00537-2016. doi: 10.1183/13993003.00537-2016
[7]	Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020, 56(1):2000535. doi:10.1183/13993003.00535-2020. doi: 10.1183/13993003.00535-2020
[8]	初乃惠, 段鸿飞. 非结核分枝杆菌病诊断与治疗. 北京: 人民卫生出版社, 2019:120-140.
[9]	Adjemian J, Prevots DR, Gallagher J, et al. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc, 2014, 11(1):9-16. doi:10.1513/AnnalsATS.201304-085OC. doi: 10.1513/AnnalsATS.201304-085OC pmid: 24236749
[10]	Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med, 2007, 101(1): 130-138. doi:10.1016/j.rmed.2006.04.002. doi: 10.1016/j.rmed.2006.04.002 URL
[11]	Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J, 2019, 54(1): 1801991. doi:10.1183/13993003.01991-2018. doi: 10.1183/13993003.01991-2018
[12]	Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. 3rd ed. Wayne: Clinical and Laboratory Standards Institute, 2018.
[13]	van Ingen J, Aksamit T, Andrejak C, et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J, 2018, 51(3): 1800170. doi:10.1183/13993003.00170-2018. doi: 10.1183/13993003.00170-2018
[14]	Jhun BW, Kim SY, Moon SM, et al. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med, 2018, 198(10):1322-1330. doi:10.1164/rccm.201802-0321OC. doi: 10.1164/rccm.201802-0321OC URL
[15]	Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis, 2017, 64(3):309-316. doi:10.1093/cid/ciw724. doi: 10.1093/cid/ciw724 URL
[16]	Flume PA, Griffith DE, Chalmers JD, et al. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians’ Interpretation of a US Food and Drug Administration Workshop. Chest, 2021, 159(2):537-543. doi:10.1016/j.chest.2020.08.2055. doi: 10.1016/j.chest.2020.08.2055 URL
[17]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11):918-946. doi:10.3760/cma.j.cn112147-20200508-00570. doi: 10.3760/cma.j.cn112147-20200508-00570
[18]	Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, 72(Suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927. doi: 10.1136/thoraxjnl-2017-210927
[19]	Griffith DE, Eagle G, Thomson R, et al. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med, 2018, 198(12):1559-1569. doi:10.1164/rccm.201807-1318OC. doi: 10.1164/rccm.201807-1318OC URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 19

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[2]	Zhu Jiankun, Meng Qian, Kong Kangbao, Jin Feng. The value of pneumonectomy in the treatment of pulmonary mucormycosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 274-281.
[3]	Fu Ying, Xiong Yangyang, Fang Si, Li Chuanxiang, Guo Hongrong. The research progress on the relationship between serum albumin and its derivative biomarkers and chronic obstructive pulmonary disease [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 231-236.
[4]	Zhao Yue, Wang Haoran, Cheng Meijin, Wang Wei, Liang Ruixia, Huang Hairong. The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 61-65.
[5]	. [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 116-120.
[6]	Liang Feng, Liu Deqing, Chen Hua, Chen Pinru, Tan Yaoju, Hu Jinxing, Zhang Danni, Xu Liuqing. Epidemiological characteristics of non-tuberculous mycobacterial disease in Guangzhou [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1373-1379.
[7]	Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076.
[8]	Tan Shouyong. Research progress on comprehensive treatment beyond antibiotic therapy for nontuberculous mycobacterium pulmonary disease [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 967-970.
[9]	Han Wenya, Zhou Yangyu, Wang Meifang, Xue Xinying. Progress in clinical diagnosis and treatment of pulmonary cryptococcosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 830-838.
[10]	Yang Chengqing, Chen Shufang, Mei Chunlin, Cao Tanze, Feng Wei, Liu Xiuping, Xu Wenjing, Du Ronghui. Clinical characteristics of 220 cases of pulmonary tuberculosis combined with chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 770-777.
[11]	Fu Keyan, Zhu Bangzheng, Ye Jian. Research progress on interstitial lung disease combined with Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 823-829.
[12]	Chai Dongyu, Qin Shuyi, Zhang Ronghua, Zou Nannan, Wang Xin. Analysis of risk factors for viral pneumonia combined with invasive pulmonary mycosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 750-755.
[13]	He Xiangrong, Chen Hua, Chen Pinru, Liang Feng, Ren Huili, Zhu Jialou, Hu Jinxing, Tan Yaoju. A case report and literature review of Mycobacterium asiaticum pulmonary disease [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 763-769.
[14]	Li Yao, Fang Zhe, Luo Danlin, Hu Yanmei, Tang Mi, Tang Zhigang, Wen Xinmin, Zhang Yong, Yao Bibo, Wang Qi, Yi Hengzhong. Clinical characteristics and prognosis of patients with novel coronavirus infection complicated with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 687-698.
[15]	Zhou Xue, He Fang, Di Yicheng, Zhang Zheng, Liu Ju. Analysis of risk factors of respiratory failure in elderly patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 357-361.